[go: up one dir, main page]

IT1302682B1 - Composizioni farmaceutiche orali contenenti buprenorfina - Google Patents

Composizioni farmaceutiche orali contenenti buprenorfina

Info

Publication number
IT1302682B1
IT1302682B1 IT1998MI002222A ITMI982222A IT1302682B1 IT 1302682 B1 IT1302682 B1 IT 1302682B1 IT 1998MI002222 A IT1998MI002222 A IT 1998MI002222A IT MI982222 A ITMI982222 A IT MI982222A IT 1302682 B1 IT1302682 B1 IT 1302682B1
Authority
IT
Italy
Prior art keywords
oral pharmaceutical
pharmaceutical compositions
compositions containing
containing buprenorphine
pharmaceutically acceptable
Prior art date
Application number
IT1998MI002222A
Other languages
English (en)
Inventor
Mauro Valenti
Original Assignee
Formenti Farmaceutici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formenti Farmaceutici Spa filed Critical Formenti Farmaceutici Spa
Publication of ITMI982222A0 publication Critical patent/ITMI982222A0/it
Priority to IT1998MI002222A priority Critical patent/IT1302682B1/it
Priority to HU0103924A priority patent/HU226166B1/hu
Priority to DE69923336T priority patent/DE69923336T2/de
Priority to JP2000576853A priority patent/JP2002527480A/ja
Priority to ES99950690T priority patent/ES2237165T3/es
Priority to CA002347195A priority patent/CA2347195C/en
Priority to AT99950690T priority patent/ATE287264T1/de
Priority to US09/807,216 priority patent/US6365596B1/en
Priority to PT99950690T priority patent/PT1121127E/pt
Priority to PCT/EP1999/007595 priority patent/WO2000023079A1/en
Priority to NZ511085A priority patent/NZ511085A/xx
Priority to SI9930736T priority patent/SI1121127T1/xx
Priority to EP99950690A priority patent/EP1121127B1/en
Priority to DK99950690T priority patent/DK1121127T3/da
Priority to AU63371/99A priority patent/AU752449B2/en
Publication of ITMI982222A1 publication Critical patent/ITMI982222A1/it
Application granted granted Critical
Publication of IT1302682B1 publication Critical patent/IT1302682B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT1998MI002222A 1998-10-16 1998-10-16 Composizioni farmaceutiche orali contenenti buprenorfina IT1302682B1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT1998MI002222A IT1302682B1 (it) 1998-10-16 1998-10-16 Composizioni farmaceutiche orali contenenti buprenorfina
PT99950690T PT1121127E (pt) 1998-10-16 1999-10-11 Composicoes farmaceuticas orais contendo buprenorfina
NZ511085A NZ511085A (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
JP2000576853A JP2002527480A (ja) 1998-10-16 1999-10-11 ブプレノルフィンを含有する経口の製薬学的組成物
ES99950690T ES2237165T3 (es) 1998-10-16 1999-10-11 Composiciones farmaceuticas orales que contienen buprenorfina.
CA002347195A CA2347195C (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
AT99950690T ATE287264T1 (de) 1998-10-16 1999-10-11 Oral anzuwendende buprenorphinhaltige arzneimittel
US09/807,216 US6365596B1 (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
HU0103924A HU226166B1 (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
PCT/EP1999/007595 WO2000023079A1 (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
DE69923336T DE69923336T2 (de) 1998-10-16 1999-10-11 Oral anzuwendende buprenorphinhaltige arzneimittel
SI9930736T SI1121127T1 (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
EP99950690A EP1121127B1 (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin
DK99950690T DK1121127T3 (da) 1998-10-16 1999-10-11 Orale farmaceutiske sammensætninger, som indeholder buprenorphin
AU63371/99A AU752449B2 (en) 1998-10-16 1999-10-11 Oral pharmaceutical compositions containing buprenorphin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002222A IT1302682B1 (it) 1998-10-16 1998-10-16 Composizioni farmaceutiche orali contenenti buprenorfina

Publications (3)

Publication Number Publication Date
ITMI982222A0 ITMI982222A0 (it) 1998-10-16
ITMI982222A1 ITMI982222A1 (it) 2000-04-16
IT1302682B1 true IT1302682B1 (it) 2000-09-29

Family

ID=11380880

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1998MI002222A IT1302682B1 (it) 1998-10-16 1998-10-16 Composizioni farmaceutiche orali contenenti buprenorfina

Country Status (15)

Country Link
US (1) US6365596B1 (it)
EP (1) EP1121127B1 (it)
JP (1) JP2002527480A (it)
AT (1) ATE287264T1 (it)
AU (1) AU752449B2 (it)
CA (1) CA2347195C (it)
DE (1) DE69923336T2 (it)
DK (1) DK1121127T3 (it)
ES (1) ES2237165T3 (it)
HU (1) HU226166B1 (it)
IT (1) IT1302682B1 (it)
NZ (1) NZ511085A (it)
PT (1) PT1121127E (it)
SI (1) SI1121127T1 (it)
WO (1) WO2000023079A1 (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368023B1 (de) * 2001-02-16 2005-12-28 Grünenthal GmbH Verwendung von buprenorphin zur therapie der harninkontinenz
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
NZ550320A (en) 2004-04-15 2010-02-26 Chiasma Inc Compositions capable of facilitating penetration across a biological barrier
DE602004017514D1 (de) * 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
US20070117828A1 (en) * 2005-11-21 2007-05-24 Schering-Plough Animal Health Corp. Pharmaceutical compositions
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
SI2915525T1 (sl) 2011-09-19 2022-01-31 Orexo Ab Sublingvalne tablete, odporne proti zlorabi, ki vsebujejo buprenorfin in nalokson
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
WO2015038327A1 (en) 2013-09-10 2015-03-19 Insys Pharma, Inc. Sublingual buprenorphine spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA2954370A1 (en) 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
AU2019209416A1 (en) 2018-01-22 2020-07-30 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605671A (en) 1984-09-28 1986-08-12 American Home Products Corporation Parenteral formulation
JPH03275622A (ja) * 1990-03-26 1991-12-06 Teisan Seiyaku Kk マレイン酸トリメブチンを含有する経口固形製剤
JPH08295637A (ja) * 1995-04-27 1996-11-12 Green Cross Corp:The 口腔部局所投与剤
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
JP3687025B2 (ja) * 1998-06-04 2005-08-24 東和薬品株式会社 安定なマレイン酸エナラプリル錠剤

Also Published As

Publication number Publication date
DE69923336D1 (de) 2005-02-24
ITMI982222A1 (it) 2000-04-16
EP1121127B1 (en) 2005-01-19
US6365596B1 (en) 2002-04-02
ITMI982222A0 (it) 1998-10-16
NZ511085A (en) 2002-10-25
WO2000023079A1 (en) 2000-04-27
AU6337199A (en) 2000-05-08
HU226166B1 (en) 2008-05-28
HUP0103924A3 (en) 2003-05-28
SI1121127T1 (en) 2005-06-30
CA2347195A1 (en) 2000-04-27
HUP0103924A2 (hu) 2002-02-28
ATE287264T1 (de) 2005-02-15
DK1121127T3 (da) 2005-05-02
JP2002527480A (ja) 2002-08-27
EP1121127A1 (en) 2001-08-08
PT1121127E (pt) 2005-03-31
AU752449B2 (en) 2002-09-19
DE69923336T2 (de) 2005-05-25
ES2237165T3 (es) 2005-07-16
CA2347195C (en) 2008-03-18

Similar Documents

Publication Publication Date Title
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
HUP0201103A3 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
IL154981A0 (en) Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
TR200003787A3 (tr) Kararli yavas salimli oral dozaj bilesimi.
ZA200410211B (en) Quinuclidine derivatives and pharmaceutical compositions containing the same.
HUP0102676A3 (en) Solid, quick dissolving pharmaceutical compositions containing cetrizine
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
WO2002004012A8 (en) Anhydrous pharmaceutical composition of vancomycin for topical use
HUP0303714A3 (en) Pharmaceutical compositions for dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
AU2001242819A1 (en) Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof

Legal Events

Date Code Title Description
0001 Granted